The GCC called Zoetis India Capability Centre will be supporting the New Jersey, US-based company’s global operations including commercial, supply chain, manufacturing and research and development, using advanced technology tools like artificial intelligence, machine learning, and data analytics. The centre will also contribute in developing AI-driven diagnostic tools and other solutions for the veterinarians and pet owners.
“We want to leverage Hyderabad’s rich tech talent pool, the life-science ecosystem and supportive government environment,” said Keith Sarbaugh, chief information officer to ET.
“Through Hyderabad GCC, we are accelerating our ability to deliver breakthrough solutions for veterinarians, pet owners and livestock farmers across the globe,” Sarbaugh added.
Anil Raghav, vice president and head of Zoetis India Capability Centre said that Hyderabad centre will become a global powerhouse for veterinary technology innovation.The global animal health market is projected to grow at a rate of 4-6% in the next five to ten years. The growth is driven by increasing pet ownership, growing medicalization of companion animals, and rising global demand for animal protein.Zoetis which demerhed from Pfizer in 2013, became a fully independent company with revenues of $8.5 billion in 2023, globally has 14,100 employees. It has the largest R&D spends among animal research companies globally, reaching $613 million in 2023.
In India the company has about 100 employees, with commercial headquarters located in Mumbai, and R&D facility in Navi Mumbai.
In India animal health market size is growing rapidly at 10-12%, driven by pet adoption, pet medicalization, and protein consumption, with potential to reach $2 billion by 2030 from current $800 million.
Zoetis in India which markets innovation led products like vaccines, monoclonal antibodies, parasiticides, proteins, and other medications.
